WASHINGTON (dpa-AFX) - Synta Pharmaceuticals Corp. (SNTA) and private firm
Madrigal Pharmaceuticals, Inc. Thursday announced a definitive merger agreement
under which Madrigal will merge with a wholly-owned subsidiary of Synta in an
Synta Pharmaceuticals stopped a Phase III trial on a lung cancer drug after investigators realized it was unlikely to meet its goals, news that plunged the biotech into penny-stock territory as management tries to figure out a way forward.
JERUSALEM (dpa-AFX) - Corbus Pharmaceuticals Holdings Inc.'s (CRBP)
investigational new drug Resunab for the treatment of cystic fibrosis has been
designated as a Fast Track development program and granted Orphan Drug
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the
Company has decided to terminate the Phase 3 GALAXY-2 trial of
ganetespib and docetaxel in the second-line treatment of patients with
advanced non-small cell...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Synta Pharmaceuticals (SNTA):